Cargando…

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study

BACKGROUND: Xanthine oxidase inhibitors are anti-hyperuricemic drugs that decrease serum uric acid levels by inhibiting its synthesis. Xanthine oxidase is also recognized as a pivotal enzyme in the production of oxidative stress. Excess oxidative stress induces endothelial dysfunction and inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oyama, Jun-ichi, Tanaka, Atsushi, Sato, Yasunori, Tomiyama, Hirofumi, Sata, Masataka, Ishizu, Tomoko, Taguchi, Isao, Kuroyanagi, Takanori, Teragawa, Hiroki, Ishizaka, Nobukazu, Kanzaki, Yumiko, Ohishi, Mitsuru, Eguchi, Kazuo, Higashi, Yukihito, Yamada, Hirotsugu, Maemura, Koji, Ako, Junya, Bando, Yasuko K., Ueda, Shinichiro, Inoue, Teruo, Murohara, Toyoaki, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912773/ https://www.ncbi.nlm.nih.gov/pubmed/27317093 http://dx.doi.org/10.1186/s12933-016-0409-2

Ejemplares similares

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study
por: Teragawa, Hiroki, et al.
Publicado: (2023)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
por: Tanaka, Atsushi, et al.
Publicado: (2016)

The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study
por: Maruhashi, Tatsuya, et al.
Publicado: (2016)

Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia
por: Wei, Shuoyu, et al.
Publicado: (2020)

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
por: Jordan, Andreas, et al.
Publicado: (2018)

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
por: Nomura, Johji, et al.
Publicado: (2014)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study
por: Saito, Yuichi, et al.
Publicado: (2022)

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
por: Higa, Yoshiki, et al.
Publicado: (2023)

Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
por: Tomiyama, Hirofumi, et al.
Publicado: (2016)

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
por: Kishimoto, Shinji, et al.
Publicado: (2023)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study
por: Yamada, Hirotsugu, et al.
Publicado: (2017)

Reduced reactive hyperemia of the brachial artery in diabetic patients assessed by repeated measurements: The FMD‐J B study
por: Masaki, Nobuyuki, et al.
Publicado: (2023)

Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics
por: Kikuchi, Hiroto, et al.
Publicado: (2012)

Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats
por: Shirakura, Takashi, et al.
Publicado: (2016)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Long-Term Inhibition of Xanthine Oxidase by Febuxostat Does Not Decrease Blood Pressure in Deoxycorticosterone Acetate (DOCA)-Salt Hypertensive Rats
por: Szasz, Theodora, et al.
Publicado: (2013)

Integrated in silico – in vitro strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic effect with allopurinol and febuxostat
por: Ghallab, Dina S., et al.
Publicado: (2022)

Brachial‐Ankle Pulse Wave Velocity Versus Its Stiffness Index β‐Transformed Value as Risk Marker for Cardiovascular Disease
por: Tomiyama, Hirofumi, et al.
Publicado: (2019)

The mechanism and significance of the conversion of xanthine dehydrogenase to xanthine oxidase in mammalian secretory gland cells
por: Kusano, Teruo, et al.
Publicado: (2022)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
por: Sezai, Akira, et al.
Publicado: (2022)

Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK
por: Nomura, Johji, et al.
Publicado: (2013)

SAT641 The Xanthine Oxidoreductase Inhibitor, Febuxostat, Protects Against Nanomaterial Inhalation-induced Endocrine, Microvascular And Reproductive Dysfunction During Gestation
por: Bowdridge, Elizabeth, et al.
Publicado: (2023)

Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients
por: Fujimura, Yuki, et al.
Publicado: (2017)

Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice
por: Mizuno, Yu, et al.
Publicado: (2019)

Febuxostat, a Xanthine Oxidoreductase Inhibitor, Decreases NLRP3-dependent Inflammation in Macrophages by Activating the Purine Salvage Pathway and Restoring Cellular Bioenergetics
por: Nomura, Johji, et al.
Publicado: (2019)

Do incretins improve endothelial function?
por: Oyama, Jun-ichi, et al.
Publicado: (2014)

Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study
por: Saito, Yuichi, et al.
Publicado: (2023)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nkv8ed73i0bhc2ocp1t0cf5dkq